Hoffmann-la Roche

This early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…

This early-stage study tests a new drug called RO7812653 in 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side effects.

This study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…

This study tests an experimental drug called Afimkibart (RO7790121) in 160 people with moderate to severe rheumatoid arthritis who did not get better with or could not tolerate standard treatments like TNF or JAK inhibitors. Participants will receive either the drug or a placebo …

This phase 3 trial tests whether adding the targeted drug inavolisib to standard maintenance therapy (Phesgo) can delay cancer growth in people with a specific genetic mutation (PIK3CA) in HER2-positive advanced breast cancer. About 230 participants who have already completed ini…

This early-stage study tests a new drug called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose injected into the spine, with some getting a pl…

This study is testing the long-term safety and effectiveness of a drug called afimkibart in people with moderate to severe rheumatoid arthritis. Participants have already taken afimkibart in a previous study and will continue taking it. The goal is to see if the drug remains safe…

This phase 3 trial is testing a once-weekly injection called enicepatide in 300 Chinese adults who are obese or overweight, with or without type 2 diabetes. The drug works by mimicking two gut hormones to reduce appetite and improve blood sugar control. Participants will receive …

This study tests whether adding a new drug (RO7268489) to the standard MS treatment ocrelizumab can slow disability progression in adults with progressive multiple sclerosis. About 360 participants will receive either the new drug or a placebo, and researchers will track walking …

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…

This study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a disease that causes inflammation and sores in the colon. The goal is to see if the drug can safely help children feel better and achieve remission (no symptoms…

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This phase 3 trial is testing a new weekly injection called enicepatide for weight loss in 2000 adults with obesity or overweight who do not have type 2 diabetes. Participants will receive either the drug or a placebo for 72 weeks. The main goal is to see how much weight they los…

This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…

This study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment based on specific biomarkers found in their tumor. The goal is to see if these per…

This study tests a refillable eye implant (Port Delivery System) that slowly releases the drug ranibizumab to treat wet age-related macular degeneration. The implant is refilled every 36 weeks, potentially reducing the need for frequent eye injections. About 250 participants who …

This study tests whether combining the drug inavolisib with other treatments can safely shrink or eliminate early-stage breast tumors that have a specific genetic change (PIK3CA mutation). About 60 people with untreated stage II-III breast cancer will receive the drug combination…

This study tests a new gene therapy called SPK-8011QQ in 5 adult men with severe or moderately severe hemophilia A. The goal is to see if it is safe and tolerable. Participants receive a one-time intravenous dose, and researchers monitor for side effects and lab changes.

This early-stage trial tests an experimental drug called RO7663498, given as an injection into the eye, for people with diabetic retinopathy. The main goal is to check safety and how the drug moves through the body. About 30 participants will receive multiple doses to see if it i…

This Phase 3 trial is testing a new weekly injection called enicepatide for weight loss in 1600 people who are obese or overweight and also have type 2 diabetes. The drug works by mimicking natural hormones that help control appetite and blood sugar. Participants will receive eit…

This clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants, from infants to adults, will receive either emicizumab or continue their current treatment. The go…

This study compares a continuous glucose monitor (CGM) to standard fingerstick testing in 270 adults with type 1 or type 2 diabetes who use insulin injections. Participants wear the Accu-Chek SmartGuide sensor to track blood sugar levels continuously. The goal is to see if the CG…

This phase 3 trial tests sefaxersen, a drug that targets a part of the immune system, in 428 people with IgA nephropathy at high risk of kidney decline. Participants receive either sefaxersen or a placebo as a shot under the skin. The main goal is to see if the drug reduces prote…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This phase 2 trial is testing whether adding a drug called inavolisib to two standard treatments (ribociclib and fulvestrant) can shrink tumors or slow cancer growth in people with advanced hormone-receptor-positive, HER2-negative breast cancer that has a specific genetic change …

This study tests a new drug, RO7771950, designed to reach the brain, for people with HER2-positive breast cancer that has spread to the brain or other organs. About 650 participants will receive either the new drug or an existing drug (tucatinib), both combined with standard ther…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Rese…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. About …

This phase 3 trial tests a drug called afimkibart in 100 children aged 2-17 with moderate-to-severe Crohn's disease. The goal is to see if it can help children feel better and heal their intestines. Participants will receive the drug as an IV infusion or injection, and researcher…

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The g…

This study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema) who have already taken it in earlier studies. About 120 adults will be followed to see how well the drug controls their eczema over time and what side effe…

This study tests a new drug called RO7790121 (Afimkibart) in people with moderate-to-severe Crohn's disease. The goal is to see if the drug can reduce symptoms and heal the gut lining better than a placebo. About 425 adults who have not responded well to other treatments will tak…

This study is testing several different drug combinations in people with advanced ER-positive breast cancer that has stopped responding to prior treatments. The trial is designed like an 'umbrella,' allowing new drug combos to be added as they become available. About 316 particip…

This study tests a drug called satralizumab in children aged 2 to 11 who have a rare autoimmune disease called NMOSD. The main goal is to see how the drug moves through the body and if it can safely reduce relapses. Only 8 children will take part, and the results will help doctor…

This Phase 3 trial tests a new drug called NXT007 (Zemocimig) against standard Factor VIII treatment to prevent bleeding in people with severe or moderate hemophilia A who do not have inhibitors. About 126 participants aged 12 and older will receive either NXT007 as a shot under …

This study tests an oral drug called fenebrutinib in 12 children and adolescents aged 10 to 17 with relapsing multiple sclerosis. The goal is to see how the drug moves through the body, how safe it is, and whether it reduces new brain lesions seen on MRI. Participants can choose …

This early-stage study tests a new daily pill, RO7795081, in 30 healthy Chinese adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body handles it. Participants will receive either the drug or a placebo, and researchers will monitor…

This Phase 3 trial tests whether trontinemab can slow down Alzheimer's in people with early symptoms like mild memory problems. About 800 volunteers will receive either the drug or a placebo by IV for 72 weeks. The study measures changes in thinking, daily function, and safety.

This study tests whether adding risdiplam, a daily oral medicine, can help children under 2 with spinal muscular atrophy (SMA) who stopped getting better or started declining after receiving gene therapy. The study will enroll 28 children and measure changes in motor skills over …

This Phase 3 trial tests satralizumab, an injected drug, in 120 people with NMDAR or LGI1 encephalitis—rare conditions where the immune system attacks the brain. The goal is to see if the drug improves disability and reduces the need for rescue treatments. Participants receive ei…

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tum…

This study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese…

This phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) to the immunotherapy drug nivolumab can prevent high-risk bladder cancer from coming back after surgery. About 62 participants will receive either the combination or nivolumab alone. The st…

This study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…

This study compares a new drug, NXT007, to an existing one (emicizumab) for preventing bleeding episodes in people aged 12 and older with hemophilia A. Participants may have severe, moderate, or mild disease, with or without factor VIII inhibitors. The goal is to see if NXT007 is…

This early-stage study is testing a new treatment for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the disease. About…

This study tests an experimental drug called prasinezumab in 900 people with early-stage Parkinson's disease who are already taking levodopa. The goal is to see if the drug can delay worsening of motor symptoms compared to a placebo. Participants receive the drug or placebo by IV…

This early-stage study tests an experimental oral drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check safety and how the drug interacts with common statins (rosuvastatin and pitavastatin). Participants will receive the drug or a placebo in …

This study tests a new drug, NXT007, in people with severe or moderate hemophilia A. The drug is given as a shot under the skin, first every two weeks, then every four weeks. The goal is to see if it is safe and helps control bleeding. About 60 adults, teens, and children will ta…

This Phase 3 study compares a new daily pill, giredestrant, against the standard shot fulvestrant, both given alongside a CDK4/6 inhibitor, in about 1,050 people with ER+/HER2- advanced breast cancer that has become resistant to prior hormone therapy. The goal is to see if girede…

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a condition that can cause rapid vision loss. About 1,000 people who have already used the implant in earlier studies will…

This study follows 800 Chinese patients with early-stage ALK-positive non-small-cell lung cancer who took alectinib after surgery to see how long they stay cancer-free. Researchers will collect real-world data on disease-free survival and patient characteristics. The goal is to u…

This study tests the drug alectinib in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to other treatments or have no standard therapy. The goal is to see if alectinib is safe and can shrink or control these tumors.…

This study tests whether a new combination of two drugs, inavolisib and enzalutamide, works better than standard treatments for men with metastatic castration-resistant prostate cancer that has progressed after one prior therapy. About 100 men will be randomly assigned to receive…

This study is observing how well the drug glofitamab works and how safe it is for Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried one prior treatment. Researchers will track 300 participants receiving glofitamab as part of t…

This Phase 3 trial tests trontinemab, an antibody given by IV, in 800 people with early Alzheimer's (mild cognitive impairment to mild dementia). Half get the drug, half get a placebo, for 72 weeks. The goal is to see if it slows decline in memory, thinking, and daily activities.

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study tests a new drug called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation in the colon. About 350 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goal is to se…

This study tests whether adding the drug inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). About 450 adults whose cancer has not been treated yet in the advanced setting will …

This early-stage trial is testing two drugs, mosunetuzumab and venetoclax, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. Mosunetuzumab is given as a shot under the skin, and venetoclax is a daily pill. The study will chec…

This early-phase study tests a new drug (glofitamab) combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 U.S. adults whose diffuse large B-cell lymphoma has returned or stopped responding to prior treatment. The main goals are to check safety and see ho…

This study looks at the long-term safety of the drug astegolimab in people with chronic obstructive pulmonary disease (COPD). It includes about 2,000 participants who already completed a one-year study with the drug. The main goal is to track any side effects that may occur with …

This study tests if obinutuzumab can help teens and children with lupus nephritis, a serious kidney complication of lupus. About 40 participants aged 5 to 17 will receive either the drug or a placebo. The goal is to see if the drug improves kidney function and reduces protein in …

This study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…

This Phase 3 study tests whether the experimental drug glofitamab works better than standard treatments (rituximab plus bendamustine or lenalidomide plus rituximab) for people with mantle cell lymphoma that has returned or not responded to prior therapy. About 182 participants wi…

This phase 3 study tests a drug called afimkibart in 600 people with moderate-to-severe Crohn's disease. Participants receive either the drug or a placebo to see if it can reduce symptoms and gut inflammation. The trial is double-blind, meaning neither patients nor doctors know w…

This study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.

This study tests the drug ocrelizumab in 60 Chinese adults with two forms of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see if it reduces relapses and controls disease activity. Participants receive ocrelizumab infusions, and researchers trac…

This study tests a new gene therapy called SPK-10001 for people with Huntington's disease. It involves a one-time infusion into specific areas of the brain. The main goal is to see if it is safe and if it can slow down the worsening of movement and daily function. About 53 adults…

This study is testing whether the drug risdiplam can improve motor skills in children under 2 with spinal muscular atrophy (SMA) who have already received gene therapy. The 28 participants will take risdiplam by mouth, and researchers will measure changes in their gross motor ski…

This study looks at how well the flu drug baloxavir marboxil works in children under 12 and whether it stops the flu from spreading to family members. About 1,100 kids with flu symptoms will take the drug, and researchers will check for drug resistance and track infections in hou…

This early-stage trial tests a new drug called RO7673396, alone or with other cancer treatments, in people with advanced solid tumors that have RAS mutations. The study has two parts: first to find a safe dose, then to see if it shrinks tumors. About 405 participants will take pa…

This study offers continued access to ocrelizumab for up to 500 people with multiple sclerosis who were already taking the drug in a previous Roche-sponsored trial. It aims to understand how MS affects daily physical activities like walking and using hands, from the patient's own…

This study aims to create a blood test that helps doctors quickly diagnose traumatic brain injury (TBI) and predict how patients will recover. Researchers will collect blood samples from 2,000 adults with suspected TBI in emergency rooms and hospitals. The goal is to find specifi…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study follows 1,000 Chinese adults with diffuse large B-cell lymphoma (a fast-growing blood cancer) who are receiving polatuzumab as part of their routine care. Researchers are tracking how long patients stay cancer-free after treatment and noting any side effects. The goal …

This study enrolls 600 adults with Huntington disease to examine specific genetic markers (SNPs) linked to the disease. Participants provide a blood sample and answer questions about their health and medications. The goal is to better understand the genetics of Huntington disease…

This early-phase study is testing whether afimkibart, an experimental drug for ulcerative colitis, changes how the body processes common medications like caffeine, warfarin, and omeprazole. About 25 people with moderate to severe active ulcerative colitis will receive afimkibart …

This early-stage study is testing a new drug called RO7806881 in healthy volunteers to see if it is safe and how the body processes it. About 128 healthy adults will receive either the drug or a placebo. The main goal is to check for side effects and measure drug levels in the bl…

This study is an early-stage trial to check the safety of a new drug called RO7763505. It involves 196 participants, first in healthy volunteers and then in people with stable coronary artery disease. The main goal is to see if the drug is safe and how the body processes it, not …

This study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment m…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab (VABYSMO) in routine clinical practice. Over two years, researchers will track vision changes, treatment schedules, and sa…

This study is a large-scale screening program to find people who may be eligible for Roche's Alzheimer's drug trials. It involves a simple blood test and a memory assessment. Up to 13,000 participants with memory concerns will be evaluated. No experimental treatment is given in t…

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This study follows 842 people with multiple sclerosis who are starting a new under-the-skin injection of ocrelizumab. Researchers will ask participants how satisfied they are with the injection after 1, 6, and 12 months. The goal is to understand patient experience, not to test t…

This study tests a digital platform that combines an app for patients and a brain-scan analysis tool for doctors. The goal is to see if it helps monitor multiple sclerosis (MS) more easily in everyday care. About 500 people with relapsing-remitting MS will use the app and have th…